Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr;30(2):524-8.
doi: 10.1007/s10637-010-9585-1. Epub 2010 Nov 12.

The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates

AeRang Kim  1 , Cindy McCully, Rafael Cruz, Diane E Cole, Elizabeth Fox, Frank M Balis, Brigitte C Widemann
Affiliations

The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates

AeRang Kim et al. Invest New Drugs. 2012 Apr.

Abstract

Purpose: Sorafenib is a small molecule inhibitor of multiple signaling kinases thought to contribute to the pathogenesis of many tumors including brain tumors. Clinical trials with sorafenib in primary and metastatic brain tumors are ongoing. We evaluated the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of sorafenib after an intravenous (IV) dose in a non-human primate (NHP) model.

Methods: 7.3 mg/kg of sorafenib free base equivalent solubilized in 20% cyclodextrin was administered IV over 1 h to three adult rhesus monkeys. Serial paired plasma and CSF samples were collected over 24 h. Sorafenib was quantified with a validated HPLC/tandem mass spectrometry assay. PK parameters were estimated using non-compartmental methods. CSF penetration was calculated from the AUC(CSF) : AUC(plasma).

Results: Peak plasma concentrations after IV dosing ranged from 3.4 to 7.6 μg/mL. The mean ± standard deviation (SD) area under the plasma concentration from 0 to 24 h was 28 ± 4.3 μg • h/mL, which is comparable to the exposure observed in humans at recommended doses. The mean ± SD clearance was 1.7 ± 0.5 mL/min/kg. The peak CSF concentrations ranged from 0.00045 to 0.00058 μg/mL. The mean ± SD area under the CSF concentration from 0 to 24h was 0.0048 ± 0.0016 μg•h/mL. The mean CSF penetration of sorafenib was 0.02% and 3.4% after correcting for plasma protein binding.

Conclusion: Sorafenib is well tolerated in NHP and measurable in CSF after an IV dose. The CSF penetration of sorafenib is limited relative to total and free drug exposure in plasma.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Plasma and cerebrospinal fluid concentration-time curves of sorafenib in non-human primates (n=3)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wilhelm SM et al. (2004) BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099–7109 - PubMed
    1. Lowy DR, Willumsen BM (1993) Function and regulation of ras. Annu Rev Biochem 62:851–891 - PubMed
    1. Rodenhuis S (1992) Ras and human tumors. Semin Cancer Biol 3 (4):241–247 - PubMed
    1. Satoh T, Kaziro Y (1992) Ras in signal transduction. Semin Cancer Biol 3(4):169–177 - PubMed
    1. Reuter CW, Morgan MA, Bergmann L (2000) Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 96(5):1655–1669 - PubMed

Publication types

MeSH terms

LinkOut - more resources